Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript

Moderna reported Q2 2025 revenues of $142 million and a net loss of $825 million, ending the quarter with $7.5 billion in cash and investments. The company demonstrated significant financial discipline, achieving a 40% year-over-year reduction in cash operating expenses and implementing a 10% workforce reduction, while revising its 2025 revenue guidance down to $1.5 billion-$2.2 billion due to a UK shipment timing shift. Operationally, Moderna secured three key FDA approvals for its next-generation COVID (mNEXSPIKE), RSV (mRESVIA), and pediatric COVID vaccines, and announced positive Phase III efficacy data for its flu vaccine, bolstering its respiratory portfolio and combination vaccine efforts. A UK patent ruling upholding infringement by Pfizer/BioNTech further strengthens its IP, as Moderna remains focused on aggressive cost reductions to achieve cash breakeven by 2028.

Analysis

Moderna's Q2 2025 results reflect a company in a strategic transition, balancing declining seasonal vaccine revenue with aggressive cost containment and promising pipeline developments. Financially, the company reported total revenues of $142 million and an improved net loss of $825 million, but revised its full-year 2025 revenue guidance down to a range of $1.5 billion to $2.2 billion. This reduction is primarily attributed to a timing shift of UK COVID vaccine shipments into Q1 2026, not a loss of volume. The central theme of the quarter was stringent financial discipline, evidenced by a 40% year-over-year reduction in cash operating expenses, an additional $400 million in planned 2025 cost savings, and a 10% workforce reduction. These measures are critical to the company's stated goal of achieving cash breakeven by 2028. Operationally, Moderna demonstrated significant progress, securing three key FDA approvals for its next-generation COVID vaccine (mNEXSPIKE), an expanded label for its RSV vaccine (mRESVIA), and a full approval for its pediatric COVID vaccine. Furthermore, positive and strong Phase III efficacy data for its seasonal flu vaccine (mRNA-1010), showing 26.6% higher relative efficacy than a licensed comparator, provides a crucial catalyst for both the standalone flu program and the future flu-plus-COVID combination vaccine. The quarter was also marked by a favorable UK patent ruling against Pfizer and BioNTech, reinforcing the value of Moderna's core mRNA technology.

Key Decisions for Investors

• Investors should shift focus from near-term COVID sales to management's execution on its aggressive cost-cutting plan, viewing progress towards the 2027 operating expense targets and the 2028 cash breakeven goal as primary performance indicators.
• Monitor key upcoming pipeline catalysts, including the delayed but potentially more comprehensive Phase III CMV data readout expected in the fall, and regulatory submissions for the seasonal flu and flu-plus-COVID vaccines, which are now supported by strong efficacy results.
• The favorable UK patent ruling against Pfizer/BioNTech strengthens Moderna's IP position and may create future value through settlements or royalties, representing a potential source of non-dilutive capital.
• While the respiratory franchise remains the core focus, progress in the intismeran oncology program with Merck, particularly the readout from the fully enrolled Phase III adjuvant melanoma trial, represents a significant long-term, non-seasonal growth driver.